ISPOR 5TH ASIA-PACIPIC CONFERENCE

[g31111]

ISPOR 5TH ASIA-PACIPIC CONFERENCE

2-4 September 2012

Taipei, Taiwan

 Kook-Hyun Cho, MA(조국현 대한민국 국민건강보험공단 징수상임이사), Managing Executive Director, National Health   Insurance  Corporation, Seoul, South Korea

Join ISPOR

| Sign up for mailing List

| Follow Us:

Monday, 3 September 2012

Sunday, 2 September >> Monday, 3 September >> Tuesday, 4 September

9:00AM - 9:15AM

WELCOME

(Translation between English-Chinese is provided)

WELCOME FROM PROGRAM Committee CO-CHAIRSYen-Huei Tarn, MS, PhD, Program Committee Co-Chair, and Executive Director, Center for Pharmaceutical Care Development, Taiwan Pharmacist Association, Taipei, Taiwan
Chee-Jen Chang, PhD, Program Committee Co-Chair, Director, Clinical Informatics and Medical Statistics Research Center, and Professor, Graduate Institute of Clinical Medical Sciences, Chang Gung University, Taoyuan, Taiwan

WELCOME FROM ISPOR ASIA CONSORTIUM EXECUTIVE COMMITTEE CHAIRSurachat Ngorsuraches, PhD, RPh, 2012-2014 ISPOR Asia Consortium Executive Committee Chair, and Associate Professor, Faculty of Pharmaceutical Sciences, Prince of Songkla University, Songkhla, Thailand

WELCOME FROM ISPOR PRESIDENTDeborah Marshall, PhD, MHSA, 2012-2013 ISPOR President, Research Chair, Health Services and Systems Research, Associate Professor, Department of Community Health Sciences, Faculty of Medicine, University of Calgary, Director, Health Technology Assessment, Alberta Bone and Joint Health Institute, Calgary, AB, Canada

WELCOME FROM TAIPEI MAYORLung-Pin Hau, Mayor of Taipei, Taipei, Taiwan

THE FUTURE OF TAIWAN HEALTH CARE SYSTEM AND POLICIES Chun Chen, Premier of the Executive Branch, Taiwan Government, Taipei, Taiwan
(Translation between English-Chinese is provided)

9:15AM – 10:45AM

FIRST PLENARY SESSION

(Translation between English-Chinese is provided)

HEALTH TECHNOLOGY ASSESSMENT IN THE SIGNIFICANTLY EVOLVING HEALTH CARE SYSTEMS IN ASIA

Health technology assessment (HTA) is a multidisciplinary process that summarizes information about the medical, social, economic and ethical issues related to the use of a health technology in a systematic, transparent, unbiased, robust way. To ensure the HTA process is successful, a health system needs the infrastructure and human capacity, adequate data sources, PE/HTA guidelines, and an understanding of the methods used in HTA. In Asia, where health systems are significantly changing and resources are severely limited, conducting or eval‎uating a health technology in Asia is a real challenge. This session will discuss the key building blocks in the development of an HTA process in the Asian context and the role of HTA in improving the health care systems in Asia.

	Moderator: Chee-Jen Chang, PhD, Director, Clinical Informatics and Medical Statistics Research Center and Professor, Graduate Institute of Clinical Medical Sciences, Chang Gung University, Taoyuan, Taiwan
	Speakers: Wen-Ta Chiu, MD, PhD, Minister of Health, Department of Health, Taipei, Taiwan (Invited)
	Kook-Hyun Cho, MA, Managing Executive Director, National Health Insurance Corporation, Seoul, South Korea
	Jie Chen, PhD, Director, Key Lab of Health Technology Assessment, Ministry of Health, Director, Center for Health Technology Assessment, Shanghai Municipal Bureau and Professor, School of Public Health, Fudan University, Shanghai, China
	Panelists: Sheldon Kong, PhD, Executive Director, Health Economics and Outcomes Research, Novo Nordisk Inc., Princeton, New Jersey, USA
	Manny Papadimitropoulos, PhD, Director, Outcomes Research, Emerging Markets, Eli Lilly and Company, Toronto, ON, Canada

10:45AM – 11:00AM

BREAK, EXHIBITS, & RESEARCH POSTER PRESENTATIONS VIEWING � SESSION I

11:00AM – 12:00PM

ISSUE PANELS & WORKSHOPS – SESSION I

11:00AM – 12:00PM

IP1: HOW TO HARMONIZE HTA AND VALUE FOR INNOVATION?
Moderator: Sang-Il Lee, PhD, MD, MPH, President, Korea Association of Health Technology Assessment (KAHTA), University of Ulsan College of Medicine, Seoul, South Korea
Panelists: Su-Kyoung Ko, PhD, Market Access Director, Pfizer Pharmaceuticals Korea Ltd., Seoul, South Korea; Eui Kyung Lee, PhD, Professor of Pharmaceutical Policy & Outcomes Research, School of Pharmacy, Sungkyunkwan University, Seoul, South Korea; Jeonghoon Ahn, PhD, MA, Senior Director, Office of Health Services Research, National Evidence-based Healthcare Collaborating Agency (NECA), Seoul, South Korea
(Translation between Chinese-English is provided)

11:00AM – 12:00PM

W1: USING INDIVIDUAL SIMULATION TO FORECAST DISEASE EPIDEMIOLOGY AND BURDEN OF ILLNESS
Discussion Leaders: Feng Pan, PhD, Research Scientist, Health Economics, United BioSource Corporation, Bethesda, MD, USA; Thitima Kongnakorn, PhD, Senior Research Associate, Heath Economics, United BioSource Corporation, Bangkok, Thailand; John Cai, PhD, Professor, China Europe International Business School, Shanghai, China

11:00AM – 12:00PM

W2: INTEGRATION OF SURVIVAL WITH QUALITY OF LIFE FOR OUTCOMES RESEARCH: SHARING OF A FREE SOFTWARE
Discussion Leaders: Jung-Der Wang, MD, ScD, Professor & Chair, Department of Public Health, National Cheng Kung University College of Medicine, Tainan, Taiwan; Jing-Shiang Hwang, PhD, Deputy Director, Institute of Statistical Science, Academia Sinica, Taipei, Taiwan; Chi-Tai Fang, MD, PhD, Associate Professor, Institute of Epidemiology and Preventive Medicine, National Taiwan University College of Public Health, Taipei, Taiwan; Mei-Chuan Hung, MPH, PhD Student, Institute of Occupational Medicine and Industrial Hygiene, College of Public Health, National Taiwan University, Taipei, Taiwan

11:00AM – 12:00PM

W3: ISSUES IN ADAPTING GLOBAL HEALTH ECONOMIC MODELS TO EMERGING MARKETS: A CONVERSATION WITH HEALTH AUTHORITIES, PHARMACEUTICAL INDUSTRY AND CONSULTANTS IN ASIA PACIFIC
Discussion Leaders: Renee J.G. Arnold, PharmD, RPh, Principal, HEOR, IMS Health, New York, NY, USA; Jianwei Xuan, MD, PhD, Senior Director & Team Leader, Pfizer, New York, NY, USA; Shanlian Hu, MD, MSc, Professor of Health Economics & Director, Center for Health Development Research, Shanghai Bureau of Health, School of Public Health, Fudan University, Shanghai, China; Kenneth K.C. Lee, MPhil, PhD, Professor of Pharmacy, Pharmacy; School of Medicine and Health Sciences, Monash University Sunway Campus, Bandar Sunway, Malaysia

11:00AM – 12:00PM

W4: CONDUCTING ONCOLOGY HEALTH SERVICES RESEARCH AND COMPARATIVE EFFECTIVENESS RESEARCH USING LARGE CLAIM DATABASES: TAIWANESE AND UNITED STATES EXPERIENCES
Discussion Leaders: Fei-Yuan Hsiao, PhD, Assistant Professor, Graduate Institute of Clinical Pharmacy, National Taiwan University, Taipei, Taiwan; Ya-Chen Tina Shih, PhD, Associate Professor, Section of Hospital Medicine, Department of Medicine and Director, Program in the Economics of Cancer, The University of Chicago, Chicago, IL, USA; Chun-Ru Chien, PhD, MD, Director, China Medical University Hospital, Taichung, Taiwan; C. Daniel Mullins, PhD, Professor, Pharmaceutical Health Services Research Department, University of Maryland School of Pharmacy, Baltimore, MD, USA

12:00PM – 3:00PM

LUNCH, EXHIBITS, & RESEARCH POSTER PRESENTATIONS VIEWING – SESSION I

12:30PM – 1:30PM

EDUCATIONAL SYMPOSIUM

CLINICAL ENDPOINTS: FINAL VERSUS SURROGATE ENDPOINT - IMPLICATIONS AND RELEVANCE FROM A PAYER, PHYSICIAN AND PATIENT PERSPECTIVE (Sponsored by Eli Lilly and Company)

Symposium Description »
(Translation between Chinese-English is provided)

1:45PM – 2:45PM

EDUCATIONAL SYMPOSIUM

REAL-WORLD EVIDENCE: MEETING THE CHALLENGE OF STAKEHOLDER NEEDS FOR DEMONSTRATING VALUE IN ASIA (Sponsored by IMS Health)

Symposium Description »

3:00PM – 4:30PM

SECOND PLENARY SESSION

(Translation between English-Chinese is provided)

INVOLVING PATIENTS & HEALTH CARE PRACTITIONERS IN HEALTH CARE DECISIONS: LEARNING FROM EACH OTHER

Health technology assessment (HTA) in Asia is a process that mainly involves specialized experts from academia, industry, and government agencies. One common observation across the region is the limited or lack of involvement by patients or health care practitioners in the process. If the HTA process is to actively engage all key stakeholder groups, patients and health care practitioners should be included. For example, the Australian Patients Association, UK’s NICE Citizens’ Council, and International Alliance of Patients’ Organizations provide valuable input on contentious subjects and collectively lobby for patient’s rights, including equity and access to health care technology. In this session, international experience on how the views of patients and health care practitioners are incorporated into HTA and health care coverage decisions will be shared, and how this experience can be adapted in Asia will be discussed and debated.

	Moderator: Yen-Huei Tarn, PhD, MS, Executive Director, Center for Pharmaceutical Care Development, Taiwan Pharmacist Association, Taipei, Taiwan
	Speakers: Sir Andrew Dillon, Chief Executive, the National Institute for Health and Clinical Excellence (NICE), London, UK
	Durhane Wong-Rieger, PhD, Chair, International Alliance of Patients' Organizations, London, UK
	Stephen Mason, LLB, BComm, DipCM, FCPA, FCSA , JP, Chief Executive Officer, the Australian Patients Association, Melbourne, VIC, Australia
	Panelists: Cheng-Hua Lee, PhD, Deputy Director General, Bureau of National Health Insurance, Taipei, Taiwan
	Tae-jin Lee, PhD, Associate Professor, School of Public Health, Seoul National University, Seoul, South Korea

4:30PM – 4:45PM

BREAK, EXHIBITS, & RESEARCH POSTER PRESENTATIONS VIEWING – SESSION I

4:45PM – 5:45PM

RESEARCH PODIUM PRESENTATIONS – SESSION I

	CANCER OUTCOMES STUDIES
4:45PM – 5:00PM	CN1	STATINS AND THE RISK OF HEPATOCELLULAR CARCINOMA IN PATIENTS WITH HEPATITIS B VIRUS INFECTION
		Tsan Y1, Lee C1, Wang J2, Chen P1 1National Taiwan University, Taipei, Taiwan, 2National Cheng Kung University College of Medicine, Tainan, Taiwan
5:00PM – 5:15PM	CN2	HOW EARLY-STAGE NON-PERSISTENCE AND NON-ADHERENCE TO ADJUVANT HORMONAL THERAPY ASSOCIATED WITH POSTMENOPAUSAL BREAST CANCER MORTALITY IN TAIWAN
		Hsieh KP1, Chen LC2, Chang CS1, Yang YH1 1Kaohsiung Medical University, Kaohsiung, Taiwan, 2University of Nottingham, Nottingham, UK
5:15PM – 5:30PM	CN3	COST-EFFECTIVESSNESS ANALYSIS OF TREATMENTS IN ADULT CANCER PATIENTS WITH LOW RISK FEBRILE NEUTROPENIA IN THAILAND
		Jamdee O1, Permsuwan U2 1Lopburi Cancer Center, Lopburi, Thailand, 2Chiang Mai University, Chiang Mai, Thailand
5:30PM – 5:45PM	CN4	INPATIENT TREATMENT PATTERNS AND HEALTHCARE EXPENDITURES FOR HEPATOCELLULAR CARCINOMA AMONG POPULATION WITH URBAN BASIC HEALTH INSURANCE IN CHINA
		Xiong X1, Li J1, Qiao Y2, Yu Z3, Zhang YJ4, Meng, W1, Zhang J1 1China Health Insurance Research Association, Beijing, China, 2Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, 3Beijing Brainpower Pharma Consulting Co. Ltd., Beijing, China, 4Sino-American Shanghai Squibb Pharmaceuticals Ltd., Shanghai, China
	COST-EFFECTIVENESS STUDIES
4:45PM – 5:00PM	CE1	THE COST-EFFECTIVENESS ANALYSIS OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV13) AND 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE (PPV23) IN TAIWAN
		Wu DBC1, Chang CJ2, Chien L2, Fang HCH3, Roberts CS4 1National Yang-Ming University, Taipei, Taiwan, 2Chang Gung University, Tao-Yuan, Taiwan, 3Pfizer, New Taipei City, Taiwan, 4Pfizer, New York, NY, USA
5:00PM – 5:15PM	CE2	COST-EFFECTIVENESS OF THE REAL-WORLD USE OF NUCLEIC ACID TEST SCREENING TO DONATED BLOOD FOR HEPATITIS B, HEPATITIS C, AND HUMAN IMMUNODEFICIENCY VIRUS: EXPERIENCE FROM TAIWAN, A COUNTRY WITH A HIGH PREVAL‎ENCE OF HEPATITIS B AND C INFECTIONS
		Wu GHM1, Wang YC1, Lin SJ2, Lin KS2 1Center for Drug Eval‎uation, Taipei, Taiwan, 2Taiwan Blood Services Foundation, Taipei, Taiwan
5:15PM – 5:30PM	CE3	HYPERBARIC OXYGEN THERAPY FOR THE TREATMENT NON-NEUROLOGICAL SOFT TISSUE RADIATION INJURIES: A COST-EFFECTIVENESS ANALYSIS
		Cronin P1, Hoggan B2, Goodall S1, Cameron A2 1University of Technology, Sydney, Broadway, NSW, Australia, 2Royal Australasian College of Surgeons, Adelaide, SA, Australia
5:30PM – 5:45PM	CE4	COST-EFFECTIVENESS OF DABIGATRAN COMPARED TO GENOTYPE-GUIDED WARFARIN DOSING FOR STROKE PROPHYLAXIS IN ATRIAL FIBRILLATION PATIENTS
		Lim KJ1, Tan DSY2, Wee HL1 1National University of Singapore, Singapore, Singapore, 2Khoo Teck Puat Hospital, Singapore, Singapore
	DIABETES OUTCOMES STUDIES
4:45PM – 5:00PM	DB1	EPIDEMIOLOGY, TREATMENT AND ECONOMIC BURDEN OF TYPE 2 DIABETES MELLITUS WITH NEPHROPATHY COMPLICATIONS IN CHINA
		Huang YY1, Fan WJ1, Zhu JJ1, Zhan L2, Chen W3 1School of Public Health, Fudan University, Shanghai, China, 2Boehringer Ingelheim Shanghai Pharmaceuticals Co. Ltd., Shanghai, China, 3Fudan University, Shanghai, China
5:00PM – 5:15PM	DB2	VITAMIN D DEFICIENCY AND DIABETES: PERCEPTIONS OF PHARMACISTS AND PHYSICIANS
		Jalundhwala F1, Majumdar A1, Malthankar S1, Jalundhwala Y2 1Bombay College of Pharmacy, Mumbai, Maharashtra, India, 2University of Illinois at Chicago, Chicago, IL, USA
5:15PM – 5:30PM	DB3	INDIRECT TREATMENT COMPARISON (ITC) OR COST EFFECTIVENESS ANALYSIS (CEA): A STUDY
		Kim H1, Gurrin L2, Liew D1 1University of Melbourne, Parkville, Victoria, Australia, 2University of Melbourne, Carlton, Victoria, Australia
5:30PM – 5:45PM	DB4	SCREENING FOR DIABETIC RETINOPATHY IN HONG KONG: IS INVERSE CARE LAW OPERATED?
		Lian JX1, McGhee SM1, Chan CKW1, Wong SH1, Yap KH2, Lam LK1, Hedley AJ1, Gangwani RA1, Chu WS3 1University of Hong Kong, Hong Kong, 2Hong Kong Polytechnic University, Hong Kong, 3Hong Kong Hospital Authority, Hong Kong
	HEALTH CARE USE AND POLICY STUDIES
4:45PM – 5:00PM	HC1	PRICE PREMIUM FOR INNOVATION? COST CALCULATION METHOD IN JAPAN VS. COST UTILITY ANALYSIS IN SOUTH KOREA
		Tan S1, Lopresti M2, Latif F3, Wasserman M3 1Double Helix Consulting, Asia-Pacific, Singapore, Singapore, 2Goddard Health, LLC, Tokyo, Tokyo, Japan, 3Double Helix Consulting, London, UK
5:00PM – 5:15PM	HC2	A REVIEW OF ECONOMIC EVAL‎UATIONS OF NEW DRUGS PRICED BY THE SIMILAR DRUG COMPARISON METHOD IN JAPAN: DID COST-EFFECTVENESS RESULTS JUSTIFY PREMIUMS?
		Kasai M1, Shiroiwa T2, Ikeda S3 1Graduate School, International University of Health and Welfare, Tokyo, Japan, 2Ritsumeikan University, Kusatsu, Shiga, Japan, 3International University of Health and Welfare, Ohtawara-city, Tochigi, Japan
5:15PM – 5:30PM	HC3	THE PROCESS OF UPDATING THE ITEMS OF NATIONAL HEALTH INSURANCE BENEFITS SCHEDULE IN TAIWAN: IS IT FAIR AND LEGITIMATE?
		Lin CW I-Shou University, Kaohsiung, Taiwan
5:30PM – 5:45PM	HC4	TAPPING INTO THE ASIAN PHARMACEUTICAL MARKET: GLOBAL FIRMS GO LOCAL?
		Wong GKW, Brooks-Rooney C, Hamerslag L, Wilson TJ, Costello S Costello Medical Consulting Ltd., Cambridge, UK
	RESEARCH ON METHODS STUDIES
4:45PM – 5:00PM	ME1	COMPARISON OF THE MEASUREMENT PROPERTIES BETWEEN THE 5-LEVEL EUROQOL GROUP'S 5-DIMENSION (EQ-5D-5L) QUESTIONNAIRE AND THE FUNCTIONAL ASSESSMENT OF CANCER THERAPY – BREAST (FACT-B) IN ASIAN BREAST CANCER PATIENTS
		Cheung YB1, Lee CF2, Luo N3, Ng R4, Wong NS4, Yap YS4, Lo SK4, Chia J4, Yee A4, Krishna L4, Wong CF1, Goh C4 1Duke - National University of Singapore Graduate Medical School, Singapore, Singapore, 2Singapore Clinical Research Institute, Singapore, Singapore, 3National University of Singapore, Singapore, Singapore, 4National Cancer Centre, Singapore, Singapore
5:00PM – 5:15PM	ME2	VALIDATION OF THE KIDNEY DISEASE AND QUALITY OF LIFE QUESTIONNAIRE (KDQOL-36) IN HAEMODIALYSIS PATIENTS IN SINGAPORE
		Yang F1, Wang VW2, Joshi VD2, Luo N3 1Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore, 2Center for Health Services Research, Singapore Health Services, Singapore, Singapore, Singapore, 3National University of Singapore, Singapore, Singapore
5:15PM – 5:30PM	ME3	CENSOR ADJUSTED NET MONETARY BENEFIT OF ANTI-HCV THERAPY IN THE VARIETY OF REAL-WORLD TREATMENT SETTING
		Hsu CN1, Kauf T2 1Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan, 2University of Florida, Gainesville, FL, USA
5:30PM – 5:45PM	ME4	USING DISCRETE CHOICE EXPERIMENTS TO VALUE HEALTH STATES FOR ECONOMIC EVAL‎UATION – THE SF-6D IN AUSTRALIA
		Norman R1, Viney R2, Brazier J3, Burgess L1, Cronin P1, King M4, Ratcliffe J5, Street DJ1 1University of Technology, Sydney, Australia, 2University of Technology, Sydney, Sydney, Australia, 3University of Sheffield, Sheffield, South Yorkshire, United Kingdom, 4University of Sydney, Sydney, Australia, 5Flinders University, Adelaide, South Australia, Australia

6:00PM – 7:00PM

RESEARCH PODIUM PRESENTATIONS – SESSION II

	CARDIOVASCULAR DISORDERS OUTCOMES STUDIES
6:00PM – 6:15PM	CV1	STATIN PRESCRIPTION IN AUSTRALIA: A COMPARISON OF DIFFERENCES IN PRESCRIBED DOSES AND POTENTIAL IMPACT ON HEALTH OUTCOMES
		Ademi Z1, Liew D2 1University of Melbourne, Melbourne, Australia, 2University of Melbourne, Parkville, Victoria, Australia
6:15PM – 6:30PM	CV2	AGE, DEMENTIA, AND EVIDENCE-BASED MEDICATION USE AFTER ADMISSION FOR ACUTE CORONARY SYNDROME
		Lin CF1, Hsiao FY1, Wu FLL1, Bai CH2, Gau CS1, Shen LJ1 1National Taiwan University, Taipei, Taiwan, 2Taipei Medical University and Shin Kong WHS Memorial Hospital, Taipei, Taiwan
6:30PM – 6:45PM	CV3	REAL-WORLD CHARACTERIZATION OF HYPERTENSION PATIENTS IN JAPAN: A 1-YEAR OVERVIEW
		Crawford B1, Ong SH2, Falvey H2 1Adelphi Values, Tokyo, Japan, 2Novartis Pharma AG, Basel, Switzerland
6:45PM – 7:00PM	CV4	ASSOCIATION BETWEEN KNOWLEDGE AND HEALTH RELATED QUALITY OF LIFE? IS PATIENT EDUCATION ALWAYS BENEFICIAL?
		Saleem F1, Hassali MA1, Shafie AA1, Aljadhey H2, Haq N1, Atif M3 1Universiti Sains Malaysia, Penang, Malaysia, 2King Saud University, Riyadh, Riyadh, Saudi Arabia, 5Allianze University College of Medical Sciences (AUCMS), Penang, Malaysia
	CLINICAL OUTCOMES STUDIES
6:00PM – 6:15PM	CL1	A NOVEL METHOD FOR CALCULATING PREVAL‎ENCE OF MULTIPLE SCLEROSIS IN AUSTRALIA
		Palmer AJ, Hitchens PL Menzies Research Institute Tasmania, University of Tasmania, Hobart, Tasmania, Australia
6:15PM – 6:30PM	CL2	USEFULNESS OF DAYS LOST DUE TO DISABILITY AS A NEW METHOD IN MEASURING BURDEN OF ADVERSE DRUG REACTIONS
		Thomas D1, Vijaya Raghavan C2, Padmanabha Reddy Y1, Kumar BM3 1RDT/RIPER, Anantapur, AP, India, 2PSG College of Pharmacy, Coimbatore, TN, India, 3JDT Islam College of Pharmacy, Kozhikode-Kerala, India
6:30PM – 6:45PM	CL3	ANTICOAGULATION CONTROL OF A PHARMACIST MANAGED ANTICOAGULATION CLINIC IN A NATIONAL REFERRAL CENTRE IN MALAYSIA
		Thanimalai S1, Shafie AA1, Ahmad Hassali MA1, Sinnadurai J2 1Universiti Sains Malaysia, Penang, Malaysia, 2Hospital Kuala Lumpur, Kuala Lumpur, Wilayah Persekut, Malaysia
6:45PM – 7:00PM	CL4	DRUG SWITCHING EVENTS AMONG USERS OF NSAIDS WITH OR WITHOUT GASTRO-PROTECTIVE DRUGS AS AN EARLY DETERMINANT OF DISSATISFACTION FROM GASTROINTESTINAL ADVERSE EVENTS
		Chen JJ, Huang YB, Wen YH, Chen SH, Yang YH Kaohsiung Medical University, Kaohsiung, Taiwan
	HEALTH CARE EXPENDITURES STUDIES
6:00PM – 6:15PM	EX1	THE EFFECTS OF POLYPHARMACY ON HEALTH CARE COSTS AND HOSPITAL ADMISSIONS IN THAI ELDERLY POPULATION: MULTIVARIATE TWO-PART MODELS
		Sruamsiri R1, Jeanpeerapong N2, Jampachaisri K3, Chaiyakunapruk N1 1Center of Pharmaceutical Outcomes Research, Muang, Phitsanulok, Thailand, 2Department of Pharmacy, Muang, Phitsanulok, Thailand, 3Department of Mathematics, Muang, Phitsanulok, Thailand
6:15PM – 6:30PM	EX2	AN OBSERVATION ON THE TREND OF OUTPATIENT CLINIC UTILIZATION AND NUMBERS OF MEDICAL PRESCRIPTION GIVEN IN TAIWAN ELDERLY BETWEEN 1997 AND 2010
		Hung YN1, Yang SY2, Wang TC3, Chen IJ1, Yu S1 1National Yang-Ming University, Taipei, Taiwan, 2Taipei City Psychiatric Center, Taipei City Hospital, Taipei, Taiwan, 3Taipei City Hospital, Taipei, Taiwan
6:30PM – 6:45PM	EX3	A EVAL‎UATION OF THE EFFECTS FROM CHINA DRUG POLICY REFORM DURING 2009-2011: SOME SUCCESS, MANY UNINTENDED EFFECTS
		Guan Q1, Cai J2, Dummett H3, Tan SC1 1Double Helix Consulting, Asia-Pacific, Singapore, Singapore, 2China Europe International Business School, Shanghai, China, 3Double Helix Consulting, London, UK
6:45PM – 7:00PM	EX4	RECENT TRENDS IN COMMUNITY PHARMACY PAYMENT OF NATIONAL HEALTH INSURANCE IN SOUTH KOREA
		Choi SE1, Cheong C2, Lee H2, Kim J2, Lim EA1 1Korea University, Yeongi-gun, Chungnam, South Korea, 2Seoul National University, Seoul, South Korea
	HEALTH TECHNOLOGY ASSESSMENT STUDIES
6:00PM – 6:15PM	HT1	WITHDRAWN
6:15PM – 6:30PM	HT2	COST-EFFECTIVENESS ANALYSIS OF BONE MINERAL DENSITY SCREENING TOOLS
		Kang E1, Lee BK2 1Soonchunhyang University, Asan city, Choongnam, South Korea, 2Soonchunhyang University, Cheonan City, Choongnam, South Korea
6:30PM – 6:45PM	HT3	DEVELOPMENT OF A CHECK LIST FOR QUALITY ASSESSMENT OF PHARMACOECONOMIC EVAL‎UATIONS SUBMITTED FOR REIMBURSEMENT IN TAIWAN
		Wu GHM1, Liao CH1, Shau WY1, Lo PC1, Pwu RF2 1Center for Drug Eval‎uation, Taipei, Taiwan, 2Taipei Medical University, Taipei, Taipei, Taiwan
6:45PM – 7:00PM	HT4	HEALTH TECHNOLOGY ASSESSMENT MAP IN ASIA – REGIONAL VERSUS INTERNATIONAL INFLUENCES
		Andreykiv M1, Wiebinga C1, Gabel C2, Zorzi O1 1Quintiles, Hoofddorp, Netherlands, 2Quintiles, Singapore, Singapore
	PREFERENCE-BASED OUTCOMES STUDIES
6:00PM – 6:15PM	PR1	DOES MEDICATION ADHERENCE CORRELATES WITH HEALTH-RELATED QUALITY OF LIFE? FINDINGS FROM A DESCRIPTIVE ANALYSIS
		Saleem F1, Hassali MA1, Shafie AA1, Aljadhey H2, Haq N1, Atif M3 1Universiti Sains Malaysia, Penang, Malaysia, 2King Saud University, Riyadh, Riyadh, Saudi Arabia, 5Allianze University College of Medical Sciences (AUCMS), Penang, Malaysia
6:15PM – 6:30PM	PR2	A FEASIBILITY STUDY OF PREFERENCE-BASED HEALTH-RELATED QUALITY OF LIFE MEASURES ON PATIENTS WITH IRRITABLE BOWEL SYNDROM IN TAIWAN
		Hsu CC1, Chen LC2, Wen YH3, Su YC4 1Kaohsiung Medical University, Kaohsiung, Taiwan, 2University of Nottingham, Nottingham, Nottingham, UK, 3Kaohsiung Medical University, Kaohsiung, Taiwan, 4Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung, Taiwan
6:30PM – 6:45PM	PR3	UTILITY VALUES FOR CHEMOTHERAPY-RELATED ADVERSE EVENTS: A REVIEW OF THE LITERATURE
		Shabaruddin FH1, Chen LC2, Elliott R2, Payne K3 1University of Malaya, Kuala Lumpur, Malaysia, 2University of Nottingham, Nottingham, UK, 3University of Manchester, Manchester, UK
6:45PM – 7:00PM	PR4	5. THE EFFECT OF NEUROPATHIC PAIN ON HEALTH STATUS, WORK PRODUCTIVITY LOSS, AND HEALTH CARE RESOURCE USE IN JAPAN
		DiBonaventura MD1, Fukuda T2, Stankus A3 1Kantar Health, New York, NY, USA, 2National Institute of Public Health, Saitama, Japan, 3Kantar Health, Princeton, NJ, USA

7:00PM – 8:00PM

RESEARCH POSTER AUTHOR DISCUSSION HOUR � SESSION I

7:00PM – 8:30PM

RESEARCH POSTER PRESENTATIONS & EXHIBITORS’ RECEPTION

8:30PM-10:00PM

ASIA CONSORTIUM RECEPTION (All attendees welcome)

Meet leaders from the Asia-Pacific region, students and newcomers particularly encouraged to attend

Sunday, 2 September >> Monday, 3 September >> Tuesday, 4 September

---

5th Asia-Pacific Conference

Contact ISPOR @ info@ispor.org  |  View Legal Disclaimer
©2012 International Society for Pharmacoeconomics and Outcomes Research. All rights reserved under International and Pan-American Copyright Conventions. 
Website design by Eagle Systems USA, Inc.

자료 더보기